Bläuenstein P, Locher J T, Seybold K, Koprivova H, Janoki G A, Mäcke H R, Hasler P, Ammann A, Novak-Hofer I, Smith A
Division of Radiopharmacy, Paul Scherrer Institute, Villigen, Switzerland.
Eur J Nucl Med. 1995 Jul;22(7):690-8. doi: 10.1007/BF01254573.
Four different methods of radiolabelling the anti-granulocyte monoclonal antibody MAb47 were compared and their influence on diagnostic value studied. The best clinical images were obtained following labelling with iodine-123 by the Iodogen method and direct labelling with technetium-99m after tris-(carboxyethyl)-phosphine treatment of MAb47 to achieve disulphide bridge reduction. 99mTc labelling using a specific ligand (MAb47-mtp), or a second method involving direct reduction with mercaptoethanol, led to an increased background activity in clinical studies, thus impeding the diagnosis of chronic disease. Fresh infections were clearly localized by all four preparations. The elimination of the activity from the blood was slower in the case of the iodinated MAb47, while the collected urine samples showed an excretion of about 10% of the injected activity per day independent of the labelling method. The results in terms of sensitivity and specificity were rather similar for all labelling methods and ranged from 90% to 99%.
比较了四种不同的抗粒细胞单克隆抗体MAb47放射性标记方法，并研究了它们对诊断价值的影响。用碘-123通过碘原法标记以及在对MAb47进行三（羧乙基）膦处理以实现二硫键还原后直接用锝-99m标记，可获得最佳临床图像。使用特异性配体（MAb47-mtp）进行99mTc标记，或采用巯基乙醇直接还原的第二种方法，在临床研究中导致背景活性增加，从而妨碍了慢性病的诊断。所有四种制剂都能清晰定位新鲜感染灶。碘化MAb47的血液中活性消除较慢，而收集的尿液样本显示，无论标记方法如何，每天排泄的注射活性约为10%。所有标记方法在敏感性和特异性方面的结果相当相似，范围为90%至99%。
